MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 186.16% ano a ano.
Virada para Lucro
O desempenho da empresa passou a ser positivo, com lucro líquido anual mais recente de US$ .
Avaliação Justa
O PE mais recente da empresa é 53.52, em uma faixa percentil média de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 171.20M ações, uma redução de 8.44% em relação ao trimestre anterior.
Mantido por Joel Greenblatt
O Super Investidor Joel Greenblatt possui 71.19K ações desta empresa.